Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Why Might Some People Opt to Take an Oral Version of Wegovy Instead of Injections? There are multiple reasons why someone ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

In the UK, anxiety, panic attacks and insomnia are not listed as possible side-effects for Ozempic, Wegovy or Mounjaro.

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...